Evidence map›Paper›PMID 38914774›Full record

Observational studyRheumatology international2024

Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: a single centre cohort study.

Grzegorz Biedroń, Mateusz Wilk, Jarosław Nowakowski, Piotr Kuszmiersz, Zofia Guła, Magdalena Strach, Alen Brkic, Glenn Haugeberg, Mariusz Korkosz

Abstract readObservational Study
In one paragraph

Observational study in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Grzegorz BiedrońDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland. grzegorz.biedron@uj.edu.pl.ORCID 0000-0002-2643-9818
Mateusz WilkDepartment of Rheumatology, Clinical Immunology and Internal Medicine, University Hospital in Cracow, Kraków, Poland.ORCID 0000-0001-7967-0880
Jarosław NowakowskiDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland.ORCID 0000-0002-8748-7581
Piotr KuszmierszDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland.ORCID 0000-0002-2031-6657
Zofia GułaDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland.ORCID 0000-0002-8698-6469
Magdalena StrachDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland.ORCID 0000-0001-5449-0680
Alen BrkicDivision of Rheumatology, Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway.ORCID 0000-0002-6371-8947
Glenn HaugebergDivision of Rheumatology, Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway.ORCID 0000-0002-9279-5191
Mariusz KorkoszDepartment of Rheumatology and Immunology, Jagiellonian University Medical College, Jakubowskiego 2, Kraków, Poland.ORCID 0000-0002-1749-9739

Funding

Narodowe Centrum Badań i Rozwoju 0026/2019-00
6 · The paper itself

Abstract

backgroundComorbidities are frequent in psoriatic arthritis (PsA) and may contribute to worse health-related outcomes. Patient-reported outcomes (PROs) are used to evaluate the burden of the assessed disease. The aim of this study is to evaluate the impact of comorbidities on selected PROs in PsA.

methodsAdult patients, diagnosed with PsA, based on CASPAR criteria, were included in this cross-sectional, observational study. Collected data encompassed the comorbidities and PROs (Health Assessment Questionnaire [HAQ], Multi-Dimensional Health Assessment Questionnaire [MDHAQ], 36-Item Short Form Health Survey [SF-36]). Standard statistic methods were performed for data assessment.

resultsThere were 267 participants included in the study (54.7% females). The most prevalent comorbidities were cardiovascular diseases (CVD) (29.2 %). Multimorbidity was observed in 50.2% cases and was associated with poorer results of SF-36 questionnaire, regarding bodily pain (34.7 [30.1, 39.3] vs. 47.5 [43.1, 52.0]; p<0.01), physical functioning (52.1 [47.3, 56.9] vs. 63.1 [58.9, 67.4]; p<0.01) and role physical (28.5 [21.2, 35.9] vs. 42.8 [35.2, 50.4]; p<0.01). CVD were associated with poorer MDHAQFn score (β=0.17, p<0.01), while mental disorders negatively influenced mental health (β= -0.35, p<0.01), vitality (β= -0.22, p<0.01), general health (β= -0.19, p<0.01), social functioning (β= -0.15, p=0.04) and role emotional (β= -0.30, p<0.01) dimensions of SF-36.

conclusionsMultimorbidity exerts significant impact on physical aspects of quality of life (QoL) in PsA. CVD and mental disorders adversely influence functional capacity as well as mental and social dimensions of QoL, respectively. The impact of comorbidities should be taken into account by clinicians and researchers assessing PROs.

Indexed as

Arthritis, PsoriaticComorbidityPatient Reported Outcome MeasuresQuality of LifeAdultAgedCardiovascular DiseasesCross-Sectional StudiesFemaleHumansMaleMiddle AgedComorbidityMultimorbidityPatient reported Outcome measurePsoriatic arthritisQuality of life

Identifiers

PMID38914774
PMCPMC11222239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.